ORKA
Oruka Therapeutics, Inc.
89.90$
-4.9%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +613.4% | +1,105.3% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -94.5% | -26.4% | – | – | – | +763.0% | -98.5% | -39.5% | -53.8% | +58.3% | +26.3% | +12.5% | -18.5% | +304.5% | +4.5% | -2.2% | +25.3% | -2.6% | -75.7% | +207.4% | |
| – | – | +6,205.7% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | -52.3% | -74.2% | -9.2% | -69.0% | – | – | +168.1% | +92.1% | +25.6% | +74.8% | +14.0% | -69.9% | -56.8% | +172.3% | +177.1% | -67.7% | -77.3% | +7,309.7% | +34.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +793.9% | -56.8% | -68.4% | +16.2% | -60.5% | -49.7% | -3.8% | +61.7% | +40.0% | +18.1% | +45.1% | +12.6% | -56.7% | -29.3% | +69.0% | +98.9% | -49.5% | -26.1% | +1,126.1% | +38.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -41.4% | -82.5% | +72.8% | +3.9% | -95.7% | -37.5% | -40.0% | – | – | – | – | – | – | – | +28.6% | – | – | – | – | -100.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.